Cargando…

Development of Buffalo Hump in the course of antiretroviral therapy including raltegravir and unboosted atazanavir: a case report and review of the literature

INTRODUCTION: The availability of raltegravir plus atazanavir provides an alternative antiretroviral strategy that may be equally efficacious and less toxic than those currently recommended in HIV treatment guidelines. In fact, this new combination antiretroviral therapy attracts the attention of th...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ceccarelli, Giancarlo, d'Ettorre, Gabriella, Marchetti, Francesco, Rizza, Cecilia, Mastroianni, Claudio M, Carlesimo, Bruno, Vullo, Vincenzo
Formato:	Texto
Lenguaje:	English
Publicado:	BioMed Central 2011
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3047431/ https://www.ncbi.nlm.nih.gov/pubmed/21329500 http://dx.doi.org/10.1186/1752-1947-5-70

Ejemplares similares

Switch to Ritonavir-Boosted versus Unboosted Atazanavir plus Raltegravir Dual-Drug Therapy Leads to Similar Efficacy and Safety Outcomes in Clinical Practice
por: Gantner, Pierre, et al.
Publicado: (2016)

Unboosted atazanavir with lamivudine/emtricitabine for patients with long-lasting virological suppression
por: Carbone, Alessia, et al.
Publicado: (2014)

Analysis of determinants of long-term efficacy of unboosted atazanavir-based regimens in the clinical setting
por: Bonora, S, et al.
Publicado: (2010)

Long-term effectiveness of unboosted atazanavir plus abacavir/lamivudine in subjects with virological suppression: A prospective cohort study
por: Llibre, Josep M., et al.
Publicado: (2016)

Purulent Meningitis as an Unusual Presentation of Staphylococcus aureus Endocarditis: A Case Report and Literature Review
por: Ceccarelli, Giancarlo, et al.
Publicado: (2011)

No difference in effectiveness of treatment simplification to boosted or unboosted atazanavir plus lamivudine in virologically suppressed in HIV-1-infected patients
por: Gutierrez-Valencia, Alicia, et al.
Publicado: (2018)

Long term effectiveness of once-daily unboosted atazanavir plus abacavir/lamivudine as a switch strategy in subjects with virological suppression
por: Llibre, Josep M, et al.
Publicado: (2014)

Switching to a 'nuke-sparing' raltegravir/atazanavir combination: an individualised approach
por: Grant, A, et al.
Publicado: (2010)

Switch to once or twice daily unboosted atazanavir in a cohort of stable HIV patients: strong differences in drug exposure and virological outcome
por: Baudry, T, et al.
Publicado: (2010)

Microbial Translocation and Infectious Diseases: What Is the Link?
por: D'Ettorre, Gabriella, et al.
Publicado: (2012)

Is previous influenza-like illness a potential Trojan horse for COVID-19?
por: Ceccarelli, Giancarlo, et al.
Publicado: (2020)

Rate and determinants of treatment response to different antiretroviral combination strategies in subjects presenting at HIV-1 diagnosis with advanced disease
por: Esposito, Antonella, et al.
Publicado: (2011)

Early Atherosclerosis in HIV Infected Subjects on Suppressive Antiretroviral Treatment: Role of Osteoprotegerin
por: D'Abramo, Alessandra, et al.
Publicado: (2013)

Probiotics and COVID-19
por: Ceccarelli, Giancarlo, et al.
Publicado: (2020)

Procalcitonin in daily clinical practice: an evergreen tool also during a pandemic
por: Russo, Alessandro, et al.
Publicado: (2021)

Antiretroviral Therapy Dampens Mucosal CD4(+) T Lamina Propria Lymphocytes Immune Activation in Long-Term Treated People Living with HIV-1
por: Lazzaro, Alessandro, et al.
Publicado: (2021)

Probiotics Reduce Inflammation in Antiretroviral Treated, HIV-Infected Individuals: Results of the “Probio-HIV” Clinical Trial
por: d’Ettorre, Gabriella, et al.
Publicado: (2015)

Preventing influenza and influenza like illness during Covid-19 pandemic: A call for action
por: d'Ettorre, Gabriele, et al.
Publicado: (2022)

Dysbiosis in SARS-CoV-2–Infected Patients
por: Marazzato, Massimiliano, et al.
Publicado: (2021)

Health-related quality of life in survivors of severe COVID-19 infection
por: d’Ettorre, Gabriele, et al.
Publicado: (2022)

Reconstitution of Intestinal CD4 and Th17 T Cells in Antiretroviral Therapy Suppressed HIV-Infected Subjects: Implication for Residual Immune Activation from the Results of a Clinical Trial
por: d'Ettorre, Gabriella, et al.
Publicado: (2014)

Clearance of human papillomavirus related anal condylomas after oral and endorectal multistrain probiotic supplementation in an HIV positive male: A case report
por: Ceccarelli, Giancarlo, et al.
Publicado: (2018)

Total thyroidectomy in HIV positive patient with buffalo hump and taurine neck
por: Carrese, Elena, et al.
Publicado: (2019)

What happens to cardiovascular system behind the undetectable level of HIV viremia?
por: d’Ettorre, Gabriella, et al.
Publicado: (2016)

Efficacy of Remdesivir-Containing Therapy in Hospitalized COVID-19 Patients: A Prospective Clinical Experience
por: Russo, Alessandro, et al.
Publicado: (2021)

Comparison of atazanavir/ritonavir and darunavir/ritonavir based antiretroviral therapy for antiretroviral naïve patients
por: Antoniou, Tony, et al.
Publicado: (2017)

A pilot study on the effects of probiotic supplementation on neuropsychological performance and microRNA‐29a‐c levels in antiretroviral‐treated HIV‐1‐infected patients
por: Ceccarelli, Giancarlo, et al.
Publicado: (2017)

Probiotics Differently Affect Gut-Associated Lymphoid Tissue Indolamine-2,3-Dioxygenase mRNA and Cerebrospinal Fluid Neopterin Levels in Antiretroviral-Treated HIV-1 Infected Patients: A Pilot Study
por: Scagnolari, Carolina, et al.
Publicado: (2016)

Raltegravir in combination with other antiretroviral agents for the treatment of HIV infection
por: Chirch, Lisa M, et al.
Publicado: (2010)

Time to Effective Therapy Is an Important Determinant of Survival in Bloodstream Infections Caused by Vancomycin-Resistant Enterococcus spp
por: Russo, Alessandro, et al.
Publicado: (2022)

Clinical Characteristics and Outcome of Patients with Suspected COVID-19 in Emergency Department (RESILIENCY Study II)
por: Russo, Alessandro, et al.
Publicado: (2021)

Brief Report: Switch to Ritonavir-Boosted Atazanavir Plus Raltegravir in Virologically Suppressed Patients With HIV-1 Infection: A Randomized Pilot Study
por: van Lunzen, Jan, et al.
Publicado: (2016)

Safety and efficacy of ombitasvir – 450/r and dasabuvir and ribavirin in HCV/HIV-1 co-infected patients receiving atazanavir or raltegravir ART regimens
por: Eron, Joseph J, et al.
Publicado: (2014)

Short-term cost analysis of raltegravir versus atazanavir + ritonavir or darunavir + ritonavir for treatment-naive adults with HIV-1 infection in the United States
por: Brogan, Anita J., et al.
Publicado: (2018)

Post-traumatic stress disorder symptoms in healthcare workers: a ten-year systematic review
por: d’Ettorre, Gabriele, et al.
Publicado: (2020)

Retinal involvement and ocular findings in COVID-19 pneumonia patients
por: Pirraglia, Maria Pia, et al.
Publicado: (2020)

Incidence of cancer and overall risk of mortality in individuals treated with raltegravir‐based and non‐raltegravir‐based combination antiretroviral therapy regimens
por: Cozzi‐Lepri, A, et al.
Publicado: (2017)

Analysis of Th17 and Tc17 Frequencies and Antiviral Defenses in Gut-Associated Lymphoid Tissue of Chronic HIV-1 Positive Patients
por: d'Ettorre, Gabriella, et al.
Publicado: (2015)

Is teicoplanin a complementary treatment option for COVID-19? The question remains
por: Ceccarelli, Giancarlo, et al.
Publicado: (2020)

Oxygen Sparing Effect of Bacteriotherapy in COVID-19
por: Ceccarelli, Giancarlo, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_egq0laqum3q2bqe84c04ul9vlg